Ziprasidone in the Psychosis Prodrome
Conditions
Psychosis Prodrome
What is the purpose of this trial?
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
Participation Guidelines
- Age:
- 16 Years - 40 Years
- Gender:
- Both
Click here for detailed information about who can participate in this trial.
- Sponsor:
- Yale University
- Dates:
- March 2008
- Last Updated:
- January 13, 2010
- Study HIC#:
- 0801003386
Clinicaltrials.gov ID: NCT00635700
For more information about this trial, contact:
Barbara Walsh, PhD
203-974-7052
barbara.walsh@yale.edu
John R Saksa, Psy.D.
203 974 7043
john.saksa@yale.edu
Scott Woods, MD
203-974-7038
scott.woods@yale.edu
Investigators
Scott Woods, MD
Principal Investigator
Joel Gelernter, MD
Sub-Investigator
Thomas McGlashan, MD
Sub-Investigator
